Pharmacy Medical News about Lung Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antivascular agents for non-small-cell lung cancer: current status and future directions
Expert Opinion on Investigational Drugs, 11/03/09

Amir E et al. – Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor, when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small–molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF–trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials.

<< Previous
Current status of maintenance therapy for advanced ovarian cancer

Next >>
Propionyl L-carnitine: intermittent claudication and peripheral...

Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09 Relevance Score: 68%

Image-Guided Radiofrequency Ablation of Lung Neoplasm in 100 Consecutive Patients by a Thoracic Surgical Service
Annals of Thoracic Surgery, 10/23/09 Relevance Score: 67%

The Association between Polymorphisms of XPD and Susceptibility of Lung Cancer: A meta Analysis
Chinese Journal of Lung Cancer, 10/21/09 Relevance Score: 67%

hsa-miR-125a-5p Enhances Invasion in Non-small Cell Lung Carcinoma Cell Lines by Upregulating Rock-1
Chinese Journal of Lung Cancer, 10/20/09 Relevance Score: 67%

CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians
Lung Cancer, 10/06/09 Relevance Score: 67%